source
- AstraZeneca halts Phase 3 lung cancer trial of volrustomig after negative resultsAstraZeneca announced on Monday that it is ending the Phase 3 study of its lung-cancer drug volrustomig after the trial failed to meet its primary efficacy endpoints. The company said the data did…
- Epic faces antitrust lawsuits and internal AI strategy turmoil ahead of annual user meetingEpic Systems, founded by Judy Faulkner, dominates the U.S. hospital electronic health record market and convenes its annual User Group Meeting with more than 20,000 attendees. The upcoming gatheri…